Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides
US7582301B1 · kind B1 · utility
5Cited by
11References
47Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 17, 2000 |
| Grant date | Sep 1, 2009 |
| Priority date | — |
| Expiry date | May 17, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.